Saif Abdulkarim Muhsin, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Phospholipase A2 | 1 | 2019 | 33 | 0.690 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 86 | 0.630 |
Why?
|
| Hypernatremia | 1 | 2016 | 82 | 0.520 |
Why?
|
| Diuretics | 1 | 2016 | 592 | 0.440 |
Why?
|
| Antithrombins | 1 | 2013 | 304 | 0.370 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1127 | 0.300 |
Why?
|
| Drug Monitoring | 1 | 2013 | 956 | 0.300 |
Why?
|
| Heparin | 1 | 2013 | 1637 | 0.270 |
Why?
|
| Graft Survival | 4 | 2021 | 3737 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2013 | 3461 | 0.200 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 66 | 0.190 |
Why?
|
| Thrombosis | 1 | 2013 | 2968 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2013 | 4599 | 0.160 |
Why?
|
| Heart Transplantation | 2 | 2020 | 3110 | 0.140 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2020 | 357 | 0.140 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 130 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 346 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 986 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 1366 | 0.110 |
Why?
|
| Amphotericin B | 1 | 2013 | 137 | 0.110 |
Why?
|
| Antibodies | 1 | 2021 | 2460 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 133 | 0.090 |
Why?
|
| Histamine H2 Antagonists | 1 | 2011 | 165 | 0.090 |
Why?
|
| Graft Rejection | 2 | 2020 | 4397 | 0.090 |
Why?
|
| Health Services Misuse | 1 | 2011 | 243 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 730 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 2538 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 4251 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 2007 | 0.080 |
Why?
|
| Critical Illness | 1 | 2020 | 2670 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3679 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 4560 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 1179 | 0.070 |
Why?
|
| Brazil | 2 | 2021 | 1270 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 2988 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 526 | 0.070 |
Why?
|
| Kidney | 2 | 2021 | 7186 | 0.060 |
Why?
|
| Europe | 2 | 2021 | 3339 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2011 | 2488 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2020 | 4776 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2020 | 2258 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2020 | 211 | 0.040 |
Why?
|
| Recurrence | 2 | 2021 | 8340 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 610 | 0.040 |
Why?
|
| Isoantigens | 1 | 2020 | 567 | 0.040 |
Why?
|
| Male | 7 | 2021 | 350118 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2020 | 679 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2020 | 810 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 162 | 0.030 |
Why?
|
| Humans | 10 | 2021 | 744343 | 0.030 |
Why?
|
| Middle Aged | 5 | 2021 | 213383 | 0.030 |
Why?
|
| Point Mutation | 1 | 2020 | 1623 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 23403 | 0.030 |
Why?
|
| Qatar | 1 | 2011 | 36 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6386 | 0.020 |
Why?
|
| United States | 4 | 2021 | 69872 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2020 | 2240 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 2540 | 0.020 |
Why?
|
| Mycoses | 1 | 2013 | 376 | 0.020 |
Why?
|
| Risk Factors | 3 | 2021 | 72290 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2029 | 0.020 |
Why?
|
| Autophagy | 1 | 2016 | 1300 | 0.020 |
Why?
|
| Female | 5 | 2021 | 380194 | 0.020 |
Why?
|
| Drug Approval | 1 | 2013 | 742 | 0.020 |
Why?
|
| Myocardium | 1 | 2020 | 4776 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4149 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5317 | 0.020 |
Why?
|
| Animals | 4 | 2020 | 168757 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 1584 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Adult | 4 | 2021 | 214055 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 18370 | 0.010 |
Why?
|
| Mice | 2 | 2020 | 81183 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 20947 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10180 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5442 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 21827 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 77449 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18029 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9727 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 23338 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40075 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7913 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57776 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 63114 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 163280 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2011 | 53288 | 0.000 |
Why?
|
| Adolescent | 1 | 2011 | 85781 | 0.000 |
Why?
|